Skip to main content

Advertisement

SpringerLink
Log in

Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

To establish the clinicopathological importance of serum p53 autoantibody (s-p53-Ab) titrations in patients with gastric cancer.

Methods

Preoperative s-p53-Ab titers were analyzed in 448 gastric cancer patients between 2010 and 2017. Seropositive patients were divided into three groups based on their antibody titers: 1.31–10.0 U/mL (low group); 10.1–100 U/mL (medium group); and > 100 U/mL (high group). We evaluated the associations between the s-p53-Abs and clinicopathological factors, carcinoembryonic antigen (CEA) levels, and cancer antigen 19-9 (CA19-9) levels. Overall survival was analyzed by multivariate analyses.

Results

A total of 72 patients (16%) were positive for s-p53-Abs. The rate of positivity for s-p53-Abs + CEA + CA19-9 was significantly higher than that for CEA + CA19-9, even in stage I gastric cancers. Gender, tumor depth, lymphatic node metastases, and distant metastases were all significantly associated with the presence of s-p53-Abs; however, overall survival was not associated with the antibodies. The patients in the high titer group (> 100 U/mL) had a relatively worse survival than those in the other groups.

Conclusions

Based on our findings, s-p53-Abs improve the overall rate of positivity for detecting gastric cancer, but the prognostic value of a high s-p53-Ab titer for predicting overall survival is limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rahman MM, Sarker MAK, Hossain MM, Alam MS, Islam MM, Shirin L, et al. Association of p53 gene mutation with helicobacter pylori infection in gastric cancer patients and its correlation with clinicopathological and environmental factors. World J Oncol. 2019;10:46–544.

    Article  Google Scholar 

  2. Yoshida T, Yamaguchi T, Maekawa S, Takano S, Kuno T, Tanaka K, et al. Identification of early genetic changes in well-differentiated intramucosal gastric carcinoma by target deep sequencing. Gastric Cancer. 2019;22:742–50.

    Article  CAS  Google Scholar 

  3. Würl P, Weigmann F, Meye A, Fittkau M, Rose U, Berger D, et al. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol. 1997;32:1147–51.

    Article  Google Scholar 

  4. Shiota G, Ishida M, Noguchi N, Takano Y, Oyama K, Okubo M, et al. Clinical significance of serum p53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol. 1998;99:41–51.

    CAS  PubMed  Google Scholar 

  5. Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer. 1999;85:302–8.

    Article  CAS  Google Scholar 

  6. Nakajima K, Suzuki T, Shimada H, Hayashi H, Takeda A, Ochiai T. Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumour Biol. 1999;20:147–52.

    Article  CAS  Google Scholar 

  7. Wu CW, Lin YY, Chen GD, Chi CW, Carbone DP, Chen JY. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer. 1999;80:483–8.

    Article  CAS  Google Scholar 

  8. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.

    Article  Google Scholar 

  9. Shimizu K, Ueda Y, Yamagishi H. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer. 2005;8:214–9.

    Article  CAS  Google Scholar 

  10. Müller M, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, et al. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol. 2006;29:973–80.

    PubMed  Google Scholar 

  11. Qiu LL, Hua PY, Ye LL, Wang YC, Qiu T, Bao HZ, et al. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect Prev. 2007;31:45–9.

    Article  CAS  Google Scholar 

  12. Mattioni M, Soddu S, Porrello A, D'Alessandro R, Spila A, Guadagni F. Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. Int J Biol Markers. 2007;22:302–6.

    Article  CAS  Google Scholar 

  13. Kunizaki M, Fukuda A, Wakata K, Tominaga T, Nonaka T, Miyazaki T, et al. Clinical significance of serum p53 antibody in the early detection and poor prognosis of gastric cancer. Anticancer Res. 2017;37:1979–84.

    Article  CAS  Google Scholar 

  14. Suzuki T, Yajima S, Ishioka N, Nanami T, Oshima Y, Washizawa N, et al. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma. Esophagus. 2018;15:294–300.

    Article  Google Scholar 

  15. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011. 10.1007/s10120–011–0041–5.

  16. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  Google Scholar 

  17. Lee JC, Lee SY, Kim CY. Yang DH Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19–9, carbohydrate antigen 72–4 levels in gastric cancer. J Korean Surg Soc. 2013;85:283–9.

    Article  Google Scholar 

  18. Tokunaga R, Sakamoto Y, Nakagawa S, Yoshida N. Baba H The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. Surg Today. 2017;47:636–42.

    Article  CAS  Google Scholar 

  19. Suzuki T, Funahashi K, Ushigome M, Koike J, Nemoto T, Shimada H. Diagnostic and prognostic impact of serum p53 antibody titration in colorectal cancer. Toho J Med. 2017;3:107–15.

    Google Scholar 

  20. Kunizaki M, Hamasaki K, Wakata K, Hidaka S, Nagayasu T, Kinoshita Y. Unusually high levels of serum p53 antibody in recurrent gastric cancer. Clin J Gastroenterol. 2017;10:503–7.

    Article  Google Scholar 

  21. Murayama K, Nanami T, Suzuki T, Oshima Y, Yajima S, Nemoto T, et al. Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery. Clin J Gastroenterol. 2017;10:357–60.

    Article  Google Scholar 

  22. Shimada H, Nagata M, Cho A, Takiguchi N, Kaimura O, Soda H, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.

    Article  CAS  Google Scholar 

  23. Xu YW, Chen H, Guo HP, Yang SH, Luo YH, Liu CT, et al. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma. Gastric Cancer. 2019;22:546–57.

    Article  CAS  Google Scholar 

  24. Hoshino I, Nagata M, Takiguchi N, Nabeya Y, Ikeda A, Yokoi S, et al. Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci. 2017;108:308–15.

    Article  CAS  Google Scholar 

  25. Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczek B, et al. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. Sci Rep. 2016;6:25467.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was partially supported by JSPS KAKENHI (grant number 26462029).

Funding

Hideaki Shimada received research grants from Medical & Biological Laboratories Co., Ltd., Nagoya, Japan.

Author information

Authors and Affiliations

  1. Department of Surgery, Toho University School of Medicine, Tokyo, Japan

    Yoko Oshima, Takashi Suzuki, Satoshi Yajima, Tatsuki Nanami, Fumiaki Shiratori, Kimihiko Funahashi & Hideaki Shimada

  2. Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan

    Hideaki Shimada

Authors
  1. Yoko Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuki Nanami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fumiaki Shiratori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kimihiko Funahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideaki Shimada.

Ethics declarations

Conflicts of interest

The other authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 111 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oshima, Y., Suzuki, T., Yajima, S. et al. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery. Surg Today 50, 1402–1408 (2020). https://doi.org/10.1007/s00595-020-02030-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-020-02030-6

Keywords

Search

Navigation